Articles: coronavirus.
-
To determine the clinical manifestations and outcomes of the coronavirus disease 2019 (COVID-19) in children who underwent liver transplantation (LT). A retrospective study was conducted at a transplant center in Thailand to include LT recipients aged < 18 years who had been infected with COVID-19. Out of a total of 54 children, there were 31 probable cases (57.4%) diagnosed using an antigen test kit and 23 confirmed cases (42.6%) diagnosed using polymerase chain reaction (14 children) or severe acute respiratory syndrome coronavirus 2 antigen (9 children). ⋯ Favipiravir was prescribed in most patients (90.7%). Only a few children had long COVID-19 or abnormal liver function tests lasting > 1 month (4 children, 7.4%, both). Pediatric LT recipients with COVID-19 during the delta and omicron variant pandemic reported mild symptoms despite undergoing immunosuppressive therapy.
-
Coronavirus Disease 2019 (COVID-19) vaccination is the most effective protective measure to control the spread of infections and provide protection against hospitalization and mortality during the pandemic. There was a necessity to measure public knowledge and acceptance for COVID-19 vaccines in different countries. Thus, the current study is aimed at evaluating the knowledge, attitude, and practice of the population in all regions of Saudi towards COVID-19 vaccination. ⋯ The level of knowledge, attitude, and practice differed based on different demographic characteristics. Regression analysis showed that having a low income, low education level, and middle-aged status, living in a village, and being married were associated with lower scores in knowledge, attitude, or practice. Targeted education and campaigns should be provided for these populations to increase their knowledge, attitude, and practice towards COVID-19 vaccination.
-
Mass vaccination is an effective method for controlling the outbreak of coronavirus disease 2019 (COVID-19) and limiting the consequent mortality due to severe COVID-19. After the second dose, immunity can decline in certain cases over time; therefore, a third booster dose should be administered. Therefore, the present study aimed to assess the immunogenicity of the third dose of the messenger ribonucleic acid BioNTech COVID-19 vaccine and determine the effect of the third booster dose of messenger ribonucleic acid COVID-19 vaccines, specifically (Oxford/AstraZeneca COVID-19 vaccine/AZD1222), BioNTech COVID-19 vaccine, and Sinopharm among healthcare workers. ⋯ In the 12th month, all 82 participants received Pfizer as a booster dose, and the highest mean SARS-CoV-2 anti-spike receptor-binding domain immunoglobulin G antibody in the 12th month belonged to those whose second dose was Pfizer (46.8835), followed by AstraZeneca (36.4635), and Sinopharm (21.7815). The Pfizer vaccine is highly effective in restoring SARS-CoV-2-specific immune responses and is well-tolerated. However, further investigation is required to determine the duration of disease protection of the third dose of the COVID-19 vaccine.
-
Vaccination against Coronavirus disease 2019 (COVID-19) has been the cornerstone of reducing morbidity and mortality of this disease, as it has been shown to decrease the risk of viral transmission, severity of disease, hospitalization, and intubation. However, true understanding of its impact is skewed by heterogeneous vaccine administration due to lack of equitable access, vaccine hesitancy, and varying social determinants of health. Therefore, this study aims to identify groups that are less likely to be vaccinated and understand whether the resultant differences in vaccination rates affect morbidity and mortality in socially marginalized COVID-19 patients. ⋯ Our study also shows that full vaccination protects against mortality and decreases the odds of intubation by 55% (adjusted odds ratio = 0.453, P value = .015) compared to no vaccination or partial vaccination. Findings from this study show an encouraging trend that sicker patients had higher rates of vaccination against COVID-19. This trend highlights the need for further identification of motivators that may be applied to vaccine-hesitant populations, which can help guide population-level policy, increase vaccination campaign yield, and reach for health equity.
-
Observational Study
Mobile COVID-19 testing program in Phoenix: A retrospective observational cohort study of results, trends, and positivity rates.
Over 3 years since the onset of the coronavirus (COVID-19), the COVID-19 pandemic remains a global health challenge. At the same time, review of the response to the current pandemic is required for planning for future pandemics and global health crises. Approximately 2.5 million cases of COVID-19 have been reported in Arizona, a state with a 7.2 million population. ⋯ Case counts and positivity rates increased during the fall and winter months, peaking in January (January 2021: 13.96% and January 2022: 24.84%). These cyclical trends cyclical can help with planning and mitigation. Continued public health awareness, including vaccinations and testing, is required in controlling COVID-19 transmission.